Skip to main content
. 2015 Dec 23;7(3):288–295. doi: 10.1111/1759-7714.12326

Table 3.

Sensitivity analysis

Increased odds of NCCRT (vs. esophagectomy) by unmeasured confounder (%) Upper end of P value for negative INB when WTP = US$150,000
1.0 0.044
1.5 0.046
2.0 0.048
2.5 0.049
3.0 0.051
3.5 0.053

Rounded at the third decimal. ICER: incremental cost‐effectiveness ratio; INB, incremental net benefit; NCCRT, neoadjuvant concurrent chemoradiotherapy; WTP, willingness‐to‐pay (in United States dollars/life‐year).